PAR 6.98% 20.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-3878

  1. 200 Posts.
    lightbulb Created with Sketch. 383
    To which I might add, given the enormous expense of bringing a copycat to market, who is going to invest that much time and capital in developing the drug knowing that it is all at risk unless they can defeat the infringement lawsuit after they bring it to market?
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.